Answer
It is an antibody–drug conjugate: trastuzumab targets HER2, while the attached DM1 component is a cytotoxic microtubule inhibitor.
Sources for this answer
- Kadcyla 100 mg and 160 mg Powder for Concentrate for Solution for Infusion — Current selected SmPCemc · Summary of Product Characteristics
- PubMedPubMed · Reputable Web
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.